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Friederike Koerber,19 Sergey Leikin,11 K. Christopher Garcia,8 Christian Netzer,1 Eckhard Scho¨nau,7
Victor L. Ruiz-Perez,14,15 Stefan Mundlos,6,20 Michael Amling,9 Uwe Kornak,6,20,* Joan Marini,5
and Bernd Wollnik1,2,3,*
We report that hypofunctional alleles ofWNT1 cause autosomal-recessive osteogenesis imperfecta, a congenital disorder characterized
by reduced bone mass and recurrent fractures. In consanguineous families, we identified five homozygous mutations in WNT1: one
frameshift mutation, two missense mutations, one splice-site mutation, and one nonsense mutation. In addition, in a family affected
by dominantly inherited early-onset osteoporosis, a heterozygous WNT1 missense mutation was identified in affected individuals.
Initial functional analysis revealed that altered WNT1 proteins fail to activate canonical LRP5-mediated WNT-regulated b-catenin
signaling. Furthermore, osteoblasts cultured in vitro showed enhanced Wnt1 expression with advancing differentiation, indicating
a role of WNT1 in osteoblast function and bone development. Our finding that homozygous and heterozygous variants in WNT1
predispose to low-bone-mass phenotypes might advance the development of more effective therapeutic strategies for congenital forms
of bone fragility, as well as for common forms of age-related osteoporosis.Introduction
Osteogenesis imperfecta (OI) is a monogenic disease
primarily characterized by dramatically increased bone
fragility and—in most cases—low bone mass.1 The pheno-
typic spectrum of OI ranges from very mild forms up to
severe and lethal types of the disease. The majority of OI
cases are inherited in an autosomal-dominant manner
and are caused by mutations in COL1A1 (MIM 120150)
and COL1A2 (MIM 120160), encoding the two a chains
of collagen type I, the predominant protein component
of the bone matrix.2 Autosomal-recessive inheritance
has also been described in nearly 10% of all OI cases. In
this form of OI, several causative mutations have been
identified in genes encoding mainly proteins involved
in collagen type I folding, modification, or matrix mineral-
ization. To date, mutations in the following genes
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Direct or indirect collagen defects result in defective
bone-matrix formation and mineralization and conse-
quently lead to impaired bone flexibility and integrity of
the skeletal system. However, collagen type I sequence
variants have been associated with reduced bone mass
and bone fragility not only in individuals suffering from
congenital OI but also in individuals with age-related
osteoporosis.14 Osteoporosis is a very common disease
affecting the skeletal system and is characterized by
reduced bone mineral density and increased fracture risk.
In contrast to that of OI, the pathophysiology of osteopo-
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osteoclast function.15,16 Common age-related osteoporosis
represents a multifactorial disease to which contributes
a combination of predisposing genetic and environmental
factors. The identification of genes underlying monogenic
diseases with altered bone mass has substantially increased
our knowledge of the key factors and pathways responsible
for skeletal development and bone homeostasis, as well as
pathogenic mechanisms predisposing to recurrent frac-
tures.1,16,17 This understanding is essential to the develop-
ment of new effective therapies for common disorders,
such as osteoporosis.18 Recently, mutations in LRP5
(MIM 603506) and other factors involved in WNT-
regulated b-catenin signaling have been shown to cause
disorders with abnormal bone mass, suggesting an
important role for this pathway in the regulation of bone
homeostasis.19–21
Here, we present genetic and functional evidence that
mutations inWNT1 cause different forms of bone fragility.
We show that homozygous loss-of-function mutations
underlie autosomal-recessive OI and that a heterozygous
WNT1mutation was inherited in an autosomal-dominant
pattern in a family with early-onset osteoporosis. Hence,
WNT1 plays a crucial role in bone formation and bone-re-
modeling processes, and this finding might facilitate the
use of more effective therapeutic strategies.Material and Methods
Subjects
All subjects or their legal representatives gave written informed
consent to the study. The study was performed in accordance
with the Declaration of Helsinki protocols and was approved by
the local institutional review boards. DNA from participating
family members was extracted from peripheral-blood lympho-
cytes by standard extraction procedures.XtremeCT
Analysis of bone microarchitecture of the nondominant distal
radius was performed by high-resolution peripheral quantitative
computed tomography (CT) (XtremeCT, Scanco Medical, Bru¨tti-
sellen, Switzerland) on five adults from a family affected by a domi-
nant heterozygous c.703C>T (p.Arg235Trp) mutation in WNT1.
The distal forearm of each affected individual was immobilized
in a carbon-fiber shell for the reduction of motion artifacts. After-
ward, the shell was fixed to the scanner and scanned as previously
described.22 An anteroposterior scout view was performed for
identifying the region of interest. Afterward, the reference line
was set at the endplate of the radius, and the measurement started
9.5 mmproximal to themanually set reference line. Subsequently,
110 CT slices—representing approximately 9 mm in the axial
direction—were obtained. Thus, we were able to analyze relative
bone volume (BV/TV), trabecular thickness (Tb.Th), cortical thick-
ness (Ct.Th), and cortical density (Dcort).Next-Generation Sequencing
Exonic and adjacent intronic sequences were enriched from
genomic DNA with the use of the Agilent SureSelect Human
Exome Kit and were run on the Illumina Genome Analyzer IIX566 The American Journal of Human Genetics 92, 565–574, April 4, 2Sequencer by Oxford Gene Technology and on the Illumina HiSeq
2000 Sequencer from the Max Planck Institute for Molecular
Genetics. Alignment was performed with the Burrows-Wheeler
Aligner, and PCR duplicates were marked with Picard tools. Local
realignment around indels, base-quality recalibration, and variant
calling were performed with the Genome Analysis Toolkit. The re-
sulting variants were annotated with Annovar and filtered accord-
ing to their genomic position, predicted effect, and frequency in
the general population from dbSNP, the 1000 Genomes Project,
the National Heart, Lung, and Blood Institute (NHLBI) Exome
Sequencing Project Exome Variant Server (EVS), and our in-house
database. Homozygous regions were defined with an in-house
script based on a hidden Markov model and on the Viterbi algo-
rithm with the use of variants found in the whole-exome
sequencing (WES) data and loci of known polymorphisms from
dbSNP. After initial discovery of the disease-causing mutation,
additional exome-sequencing data were analyzed with the
GeneTalk platform.23
mRNA Analysis ofWNT1 Transcripts
RNA of the affected individual was extracted from fresh bloodwith
the Paxgene Blood RNA system (QIAGEN, Hilden, Germany). RT-
PCR was performed via RevertAid First Strand cDNA Synthesis Kit
(Thermo Scientific, Schwerte, Germany). RT-PCR products were
used for WNT1-specific PCR amplification. The complete open
reading frame (1,113 bp) of WNT1 was amplified with primers
50-ATGGGGCTCTGGGCGCTGTTG-30 (forward) and 50-TCACA
GACACTCGTGCAGTAC-30 (reverse) and was separated on 1%
agarose gel. The PCR product of this cDNA showed a dramatically
reduced amount of WNT1 transcripts.
Generation ofWNT1 Constructs
The coding sequence of human WNT1 cDNA (RefSeq accession
number NM_005430.3) was cloned into the pCDNA3 expression
vector. The mutant variants of WNT1 were generated by site-
directed mutagenesis with a primer containing the specific nucle-
otide substitutions. The cDNA sequences of all constructs were
confirmed by Sanger sequencing.
Modeling ofWNT1 Mutations
The WNT1 substitutions p.Gly177Cys and p.Arg235Trp are
positioned within regions of conserved secondary structure,
restricted by conserved disulfide bonds, and surrounded by
conserved amino acids between XWnt8 and WNT1, making
structure-based manual modeling into the XWnt8 structure
(pdb 4F0A) the method of choice and prediction reliable. For
modeling the p.Gly177Cys and p.Arg235Trp substitutions into
the XWnt8 structure, the corresponding side chains of the
WNT1 changes and the nearby residues, which differ between
XWnt8 and WNT1 (e.g., Thr136, Val139, Glu217), were built
manually in COOT,24,25 and clashes were inspected with
MolProbity. Rotamers shown in Figure 5 produced the fewest
clashes.
Luciferase Assay
Human embryonic kidney (HEK) 293T cells cultured in Dulbec-
co’s modified Eagle’s medium containing 10% fetal bovine serum
(Life Technologies, Darmstadt, Germany) and antibiotics were
plated in 24-well plates 18 hr prior to transfection. Transient
transfections were performed in triplicate with FuGeneHD
(Roche, Mannheim, Germany) according to the manufacturer’s013
instruction with the following expression constructs: wild-type
(WT) WNT1 and mutant variants of WNT1 (200 ng), LRP5
(200 ng), MESDC2 (80 ng), Topflash (100 ng), and pRL-TK
(5 ng). For ensuring equal amounts of DNA, 200 ng LacZ-
pCDNA3.1 was used in WNT1-negative transfections. Thirty
hours after transfection, cells were lysed and frozen in lysis buffer
overnight at 20C so that lysing efficiency would increase. After
thawing, luciferase activity was measured with a Dual-Luciferase
Reporter Assay Kit (Promega,Mannheim, Germany) and a Glomex
96-microplate luminometer. Each transfection was measured in
triplicate.Osteoblast Culture
Primary mouse osteoblasts were obtained by sequential collage-
nase digestion of calvariae from newborn C57/BL6WTmice. Cells
were seeded at high density on 6-well plates in alpha minimum
essential medium (MEM) (Lonza, Cologne, Germany) containing
10% fetal calf serum (Life Technologies, Darmstadt, Germany),
Pen/Strep (Lonza, Cologne, Germany), and 2 mMUltraGlutamine
(Lonza, Cologne, Germany). When cells reached confluence,
alpha MEM was supplemented with 50 mM L-ascorbate-2-phos-
phate (Sigma, Steinheim, Germany) and 10 mM beta glycero-
phosphate (Sigma, Steinheim, Germany) for inducing osteoblast
differentiation. Osteoblasts started forming visible mineral deposi-
tion at day 9. Every 3 days, RNA was isolated with RNA-Pure
(Peqlab, Erlangen, Germany).Expression Analysis
Tissue specimens were shock frozen in liquid nitrogen after
dissection. After pulverization, RNA was isolated with the Trizol
(Life Technologies, Darmstadt, Germany) method. Total cDNA
from tissue or cultured osteoblasts was transcribed by the
RevertAidTM H Minus First Strand cDNA Synthesis Kit (Fermen-
tas, St. Leon-Rot, Germany) with random hexamer primer. Quan-
titative PCR was performed with EvaGreen (Solis Biodyne, Tartu,
Estonia) on ABI Prism 7500 (Applied Biosystems, Foster City, CA,
USA). Data were analyzed by the ABI Prism SDS Software package
according to the cycle-threshold method with the use of GAPDH
expression as a reference. All primer sequences are available upon
request.Results
A HomozygousWNT1 Mutation Causes OI in a Large
Turkish Family
We examined a consanguineous Turkish family (family 1)
with three affected individuals diagnosed with OI in two
different branches of the family (Figure 1A). Affected indi-
viduals showed typical clinical OI features, including early-
onset recurrent fractures (Figure 1B), bone deformity,
significant reduction of bone density, short stature, and
bluish sclerae in some of the affected individuals. Tooth
development and hearing were normal (Table 1). After
exclusion of all described genes for autosomal-recessive
OI by haplotyping or direct sequencing, we performed
WES in affected person V:1 of the family. For WES data
analysis, we applied a combination of determining homo-
zygous stretches with all WES variants and filtering for
novel and likely protein-affecting variants. By this filteringThe Amstrategy, we reduced the number of likely causative vari-
ants to 11, and all of them were located within the ten
largest stretches of homozygosity (Tables S1–S3, available
online). These variants were not annotated in dbSNP132,
the 1000 Genomes Database, or the EVS.
The only variant predicted to be functionally detri-
mental was a homozygous 1 bp duplication, c.859dupC
in WNT1 (RefSeq NM_005430.3, MIM 164820), located
within a large homozygous region in 12q13 (Figure S1
and Table S2). Sanger sequencing and microsatellite-
marker analysis confirmed cosegregation of the mutation
and the disease-causing haplotype. All affected individuals
are homozygous for the c.859dupC mutation, whereas
their parents are heterozygous carriers (Figure 2A and
Figure S1). The 1 bp duplication in WNT1 is predicted to
lead to a frameshift and early truncation of the C-terminal
part of the protein (p.His287Profs*30).
Mutational Spectrum ofWNT1 in Autosomal-
Recessive OI
Sequencing of the entire WNT1 coding region in 11
additional autosomal-recessive-OI-affected families, for
which all known genes affected in OI had been excluded,
identified four additional homozygous mutations in
consanguineous OI-affected families (Figure 1A and Table
1): two missense mutations (c.529G>T [p.Gly177Cys]
and c.893T>G [p.Phe298Cys]), an exon 3 donor-splice-
site mutation (c.624þ4A>G), and a nonsense mutation
(c.565G>T [p.Glu189*]; RefSeq NM_005430.3) (Figure 2A).
We used cDNA from the affected individual carrying the
putative donor-splice-site mutation c.624þ4A>G to verify
the effect of the mutation on splicing of the WNT1 tran-
script. Interestingly, we observed that, compared to the
control, the mutation caused a dramatic reduction in
normal WNT1 transcripts. This result suggests that the
c.624þ4A>G mutant transcripts might be unstable and
degraded by nonsense-mediated mRNA decay (Fig-
ure 2B). The c.529G>T mutation substitutes the highly
conserved glycine at position 177 to cysteine, whereas
the c.893T>G mutation leads to the substitution of a
cysteine for a phenylalanine at position 298 (Figures 2A,
2C, and 2D). None of the identified mutations are listed
in >13,000 alleles of the EVS. Our genetic data establish
recessive mutations in WNT1 as a cause of autosomal-
recessive OI.
Interestingly, we observed different clinical severity of
the phenotype in OI caused byWNT1mutation; it ranged
from moderate to progressively deforming forms, which
can occasionally lead to early infant death (Figures
1B–1D and Table 1).
A DominantWNT1 Mutation Causes Early-Onset
Osteoporosis
Concurrently, WES of two affected individuals from a
four-generation family (Figure 3A) affected by early-onset
osteoporosis and fractures inherited in an autosomal-
dominant pattern revealed no mutations in describederican Journal of Human Genetics 92, 565–574, April 4, 2013 567
Figure 1. Families Affected by Autosomal-Recessive OI
(A) Pedigrees of four Turkish families (families 1–4) and one Egyptian family (family 5) affected by autosomal-recessive OI.WESwas done
on DNA from affected member V:1 of family 1.
(B) X-rays of family 1 individual IV:1, who harbors the homozygous p.His287Profs*30 WNT1 variant, show a fracture.
(C) Lateral spine X-rays of the family 2 member with the homozygous WNT1 p.Gly177Cys substitution. An X-ray was taken at the start
of treatment with bisphosphonates (left). The vertebrae are severely compressed and deformed, and even after 4 years of treatment with
bisphosphonates, no improvement in size or shape is visible in the lumbar spine (right).
(D) An X-ray of individual II:3 (family 5), who has p.Phe298Cys in WNT1, shows severe deformities of the legs.genes affecting bone mass but did reveal that the
heterozygous c.703C>T variant in WNT1 segregates with
the phenotype in the family (Figures 3A and 3B). This
mutation is predicted to lead to a substitution of the
arginine at position 235 to tryptophan (p.Arg235Trp).
This variant is not found in over 13,000 alleles listed in
the EVS. Affected family members clinically showed recur-
rent fractures (for example, of vertebrae and ribs after
minor trauma beginning in adolescence), low-bone-turn-
over markers, and a reduction of trabecular and cortical
bone as revealed by high-resolution CT (Figure 3C and
Table S4). Interestingly, when performing bone-density
measurements in parents of two of our recessive OI cases,
we found that one father harboring the heterozygous
c.859dupC (p.His287Profs*30) mutation showed signs of
early-onset osteoporosis at the age of 42 years, whereas
bone density was in the lower normal ranges in the other
parents.568 The American Journal of Human Genetics 92, 565–574, April 4, 2Functional In Vitro Effects of IdentifiedWNT1
Mutations
To examine whether the identifiedWNT1mutations have
compromising effects on canonical WNT-regulated b-cate-
nin signaling transduction, we performed a dual luciferase
reporter assay. Here, we used the TOPFlash vector as
a reporter containing the coding sequence of firefly lucif-
erase downstream of TCF binding sites. The canonical
WNT-mediated signal triggers the expression of firefly lucif-
erase, and the enzymatic activity of luciferase can be quan-
tified. Initially, we showed that WT WNT1 can bind LRP5
and activate WNT-regulated b-catenin signaling (Figure 4).
Subsequently, coexpression of LRP5 and constructs encod-
ing the p.Gly177Cys, p.His287Profs*30, and p.Arg235Trp
variants showeda significant reduction in luciferase activity
in this in vitro assay. This result clearly indicates that all
three tested mutations almost completely fail to activate
the WNT-regulated b-catenin signaling cascade (Figure 4).013
Table 1. Clinical Findings in Individuals with Autosomal-Recessive OI
Family 1 Family 2 Family 3 Family 4 Family 5
IV:1 V:1 V:2 IV:3 IV:1 II:1 II:1 II:2 II:3
Sex male female male female male male female male male
Disease severity moderate moderate severe (exitus at 5 months of age) moderate severe severe severe severe severe
Skeletal Findings
Multiple fractures of extremities yes yes yes yes yes yes yes yes yes
Age at first fracture (months) 3 1 day after birth in utero 2 7 in utero 3 days after birth 1 10 days after birth
Vertebral fractures no no no yes yes yes no no no
Bowing of upper extremities yes no yes no no yes yes yes yes
Bowing of lower extremities yes yes no yes yes yes yes yes yes
Shortening of upper extremities yes no no no no yes yes yes yes
Shortening of lower extremities yes no no yes yes yes yes yes yes
Other Findings
Color of sclera white bluish gray blue blue white white faint blue faint blue blue
Dentinogenesis imperfecta no no no no no no no no no
Hypermobility of joints no no no no no no yes yes yes
Cardiac impairment no no no no no no no no no
Hearing impairment no no no no no no no no no
Intellectual development normal normal delayed normal normal normal normal normal normal
Therapy
Bisphosphonate treatment no yes no yes yes yes yes yes yes
Molecular basis
WNT1 alteration p.His287Profs*30 p.His287Profs*30 p.His287Profs*30a p.Gly177Cys c.624þ4A>G p.Glu189* p.Phe298Cys p.Phe298Cys p.Phe298Cys
aCaused by a familial mutation; DNA not available for testing.
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Figure 2. Homozygous Mutations in WNT1 in Autosomal-Recessive Families
(A) Chromatograms of identified recessive WNT1 mutations (red arrows) in comparison to the respective sequence.
(B) mRNA analysis of WNT1 transcripts in the affected individual harboring the homozygous c.624þ4A>G splice-site mutation. The
PCR product of analyzed cDNA shows a drastically reduced amount of WNT1 transcripts.
(C and D) A schematic genomic overview of WNT1 (C) and WNT1 (D) indicates the localization of the identified WNT1 mutations.
WNT1 domains were predicted on the crystal structure of XWnt8.Structural Effects ofWNT1 Mutations in a Protein
Model
In order to gain insights into the pathogenic effects
of dominant and recessive WNT1 missense mutations,
we modeled the recessive p.Gly177Cys and dominant
p.Arg235Trp substitutions on the crystal structure of
XWnt8, which has been recently described.26 Gly at posi-
tion 177 is highly conserved in human WNTs in order to
allow close packing of helices C and D within the WNT
7-helix bundle (Figure 5). In the p.Gly177Cys substitution,
the side chain of Cys177 would point into the core of the
helical bundle (within the interface to helix D), resulting in
separation of the close van der Waals packing within this
helical core. This disruption of the tight packing would
most likely lead to destabilization and perhaps to unfold-
ing of the WNT1 core, which is thought to be responsible
for binding to LRP5/6 (Figure 5).
Arg235 is located within the b-stand B at the base of the
lipid-modified b-hairpin and is surrounded by residues
conserved between WNT1 and XWnt8. In human WNTs,
position 235 is occupied by either small amino acids or
amino acids with long and flexible side chains and is
surrounded by several other well-structured amino acids.
The Trp side chain in the p.Arg235Trp mutant would clash
with the side chains of Trp233, Arg141, and Asp172 and
probably disrupt the structure of WNT1’s thumb region,
which seems to be important for interaction with FZ
proteins (Figure 5). In summary, both missense changes
are predicted to disturb the formation of the LRP5/6-
WNT1-FZ complex.
Wnt1 Expression in Osteoblasts
Wnt1 is known to be strongly expressed during neuronal
development, and its complete inactivation in knockout570 The American Journal of Human Genetics 92, 565–574, April 4, 2mice leads to a lethal phenotype as a result of malfor-
mation of the midbrain and cerebellum.27 To examine
expression of Wnt1 in the osteoblast lineage, we used
quantitative PCR to measure mRNA levels in cultured cal-
varial osteoblasts and found enhanced Wnt1 expression
with advancing differentiation. The efficient differentia-
tion was confirmed by the expression of osterix (Sp7) and
sclerostin (Sost), which are marker genes for osteoblasts
and terminally differentiated osteoblasts, respectively
(Figure 6A). Furthermore, Wnt1 expression increased in
postnatal compared to embryonic long bones (Figure 6B).
This might indicate that in the bone compartment,
WNT1 influences the osteoblast lineage itself or some adja-
cent cell type.Discussion
We report that hypofunctional alleles ofWNT1 cause low-
bone-mass phenotypes in humans.Whereas recessively in-
herited reduction in WNT1 function underlies congenital
OI, the fact that a heterozygous WNT1 mutation predis-
poses to early-onset osteoporosis implies a dominant
effect. Altered WNT1 proteins lose the ability to acti-
vate LRP5-mediated WNT-regulated b-catenin signaling
in vitro. Although this demonstrates the functional effects
of the mutations, it is currently not clear whether WNT1
also interacts with LRP5 in vivo. In order to gain more
insights into the functional difference of recessive versus
dominantmissensemutation, wemodeled bothmutations
on the crystal structure of XWnt8.26 One plausible
scenario why the p.Arg235Trp variant acts dominantly is
that p.Arg235Trp destabilizes the b-stand that supports
the lipid containing the ‘‘site 1’’ Fz-CRD binding loop.013
Figure 3. A Dominant WNT1 Mutation
in a Family Affected by Early-Onset
Osteoporosis
(A and B) Pedigree of the family with
autosomal-dominant early-onset osteopo-
rosis (A) and chromatogram of the identi-
fied heterozygous WNT1 substitution
p.Arg235Trp (B). Note that individual
IV:2 has the p.Arg235Trp variant but is
too young to be symptomatic.
(C) Analysis of bone microarchitecture.
Bone microarchitecture of the distal
radius as assessed by high-resolution
peripheral quantitative CT (XtremeCT,
Scanco Medical, Switzerland) is observed
in the family harboring the dominant
heterozygous p.Arg235Trp substitution.
Combined bone loss affecting both the
cortical and the trabecular compartments
was detected in family members with
heterozygous p.Arg235Trp changes, but
not in unaffected family members.
Figure 4. Functional Analysis of WNT1 Mutations
Dual luciferase reporter assay measuring the canonical WNT
signaling activity in HEK293T cells after coexpression of
LRP5, MESDC2, and WT or mutant WNT1 variants (encoding
p.Gly177Cys, p.His287Profs*30, or p.Arg235Trp) or LacZ-pcDNA3
(pcDNA3) as negative controls. The graph displays relative lucif-
erase activity (average and SDs) of four independent experiments,
which were performed in triplicate each time.Because WNT is roughly divided into two nearly autono-
mous domains,28 the remaining regions, including the
site 2 ‘‘index finger’’ Fz-CRD binding site and the region
proposed to engage Lrp5/6, would remain intact.26 Thus,
this mutation could potentially allow WNT1 to retain
some binding to Fz in a similar fashion to the ‘‘mini-
Wnt,’’26 but not produce a signal, thereby converting
WNT1 into a dominant-negative antagonist. This repre-
sents an attractive model-based hypothesis for future func-
tional work. Collectively, both the p.Arg235Trp and the
p.Gly177Cys substitutions would certainly appear to be
deleterious to WNT structure given their positions in core
regions of the molecule; this is in contrast to surface
mutants, which would generally not exert such structural
destabilization. It is of interest that in addition to the early
onset in the family affected by osteoporosis caused by the
heterozygous p.Arg235Trp substitution, an early onset of
reduced bone mineral density without fractures was also
observed in one of the heterozygous carriers of a recessive
WNT1 mutation. Hence, the p.Arg235Trp substitution
does not necessarily have to exert a dominant-negative
effect. Screening of larger cohorts of persons with early-
onset osteoporosis is needed for determining the fre-
quency of predisposing WNT1 variants.
WNT1 was described as an important regulator of brain
development in mice.27 We determined that Wnt1 is ex-
pressed in bone tissue as well and provide evidence thatThe American Journal of Humanthe osteoblast lineage is a site of
expression. Although their exact
expression patterns during osteoblast
differentiation are not yet known,
multiple lines of evidence suggest
a key role for LRP5 and LRP6 in
cell-fate decision, proliferation, and
differentiation of osteoblast lineage
cells.29 It is interesting to note thatheterozygous loss of WNT3A andWNT5A leads to reduced
trabecular bone mineral density to an extent similar to
that of homozygous loss of WNT10B.30,31 Furthermore,
WNT16 was recently described to especially influenceGenetics 92, 565–574, April 4, 2013 571
Figure 5. Consequences of WNT1 Muta-
tions on Crystal Structure
Modeling of the recessive WNT1
p.Gly177Cys and dominant p.Arg235Trp
substitutions. The highly conserved Gly
at position 177 (top right panel) allows
close packing of helices C and D within
the Wnt 7 a-helical core. The mutant
Cys177 side chain is likely to clash with
helix D, impairing the helix C and D inter-
face and destabilizing the Wnt1 core.
Arg235 is located within the AB b-hairpin,
and the Trp side chain of the p.Arg235Trp
mutant is likely to clash with the Trp233,
Arg141, and Asp172 side chains, destabi-
lizing the AB b-hairpin and Fz-ECD
binding site. The altered protein could
retain Fz and LRP5/6 binding but lose its
ability to activate signaling, resulting in
a dominant-negative effect.cortical bone in a human genome-wide association study
(GWAS) and in a knockout mouse model.32,33 Our
analysis of bone structure in several individuals with
WNT1 mutations revealed a similar cortical thinning
and reduced trabecular density (Figure 3C). Currently, no
data on the skeletal phenotype ofWnt1-deficient or -over-
expressing mice are available, which might be due to
the fact that the focus has been restricted to the role of
WNT1 in the CNS and in tumor formation.34 WNT1
overexpression in human mesenchymal stem cells was
shown to reduce their osteogenic and adipogenic dif-
ferentiation but to induce osteogenic differentiation in
neighboring non-WNT1-expressing WT cells.35 This
indicates that depending on the strength of WNT1-
induced stimulation of the canonical pathway, WNT1
has a double role in stem cell maintenance and osteogenic
differentiation.35
Interestingly, a recent GWAS found SNPs located near
WNT1 in chromosomal region 12q13 to be associated
with the risk of low bone mass.32 This, together with our
observations that WNT1 can activate LRP5-mediated
WNTsignaling and that mutations inWNT1 cause reduced572 The American Journal of Human Genetics 92, 565–574, April 4, 2013bone mass and bone fragility,
supports the idea that WNT1 is one
of the physiological LRP5 ligands
inducing canonical WNT signaling
in osteoblast-lineage cells. In all indi-
viduals with OI due to WNT1 muta-
tions, therapy with bisphosphonates
did not show a substantial effect.
This absence of a therapeutic effect
is in line with a dysfunction of osteo-
blasts in individuals carrying WNT1
mutations but does not apply to
children with OI caused bymutations
in COL1A1/2; in this form of OI,
the defect provokes a high turnover
state of bone, and a positive effectis observed when osteoclast function is blocked with
bisphosphonates.
None of the individuals harboring heterozygous or
homozygous WNT1 mutations had ataxia, other signs of
cerebellar dysfunction, or intellectual disability; the only
exception was family 1 individual V:2, who presented
with brain malformation and developmental delay.
Further studies of individuals with mutations in WNT1
and osteopenic bone diseases will be necessary in the
future for establishing whether neurologic complications
can be associated in individuals with WNT1 mutations.
In contrast, Wnt1-knockout mice and the spontaneous
swaying (sw) mutant show variable hypoplasia of the cere-
bellum and midbrain structures, respectively, leading to
ataxia in surviving animals.27,36 One explanation for this
discrepancy could be a milder effect of the human muta-
tions. However, our in vitro experiments clearly showed
a loss of the ability of the missense and the frameshift vari-
ants to induce canonical WNT signaling. The p.Glu189*
nonsense change astonishingly truncates the protein
exactly in the same position as does the murine sw
mutation, thus proving its loss-of-function effect.36 An
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Figure 6. Expression of Wnt1 in Cultured Osteoblasts and Long
Bones
Wnt1 expression analysis by quantitative PCR.
(A)With advancing differentiation, in vitro cultured calvarial oste-
oblasts show moderately increasing Wnt1 expression. Osteoblast
differentiation markers Sp7 and Sost prove efficient differentiation
of osteoblast cultures used for measurement of Wnt1 expression.
(B) Quantitative Wnt1 mRNA analysis in long bones shows
enhanced expression with increasing age from embryonic day
14.5 (E14.5) to postnatal week 6 (6W). Error bars represent SDs;
n¼3 for each specimen analyzed.alternative explanation could be that in the cocktail of
WNT proteins during brain development, loss of WNT1
leads to a critical bottleneck situation in mice, but not in
humans.
Our finding that homozygous and heterozygous variants
in WNT1 predispose to low-bone-mass phenotypes and
bone fragility might facilitate the use of more effective
therapeutic strategies. In this context, it is interesting to
note that the pharmacological block of WNT-signaling
antagonists, such as sclerostin, is currently under investi-
gation in clinical trials.18 The findings presented in our
paper provide additional evidence that this might be an
effective therapeutic option in these individuals with
low-bone-mass phenotypes.Supplemental Data
Supplemental Data include one figure and four tables and can be
found with this article online at http://www.cell.com/AJHG.Acknowledgments
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